Pages that link to "Q36868792"
Jump to navigation
Jump to search
The following pages link to In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity (Q36868792):
Displaying 50 items.
- Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer (Q33429758) (← links)
- Cytokine-induced NK-like T cells: from bench to bedside (Q33762499) (← links)
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects (Q33887452) (← links)
- IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study (Q34077847) (← links)
- Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. (Q34329186) (← links)
- Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". (Q34367252) (← links)
- Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. (Q34568892) (← links)
- CD8+CD44hi but not CD4+CD44hi memory T cells mediate potent graft antilymphoma activity without GVHD (Q34707286) (← links)
- HDAC inhibition and graft versus host disease (Q35016985) (← links)
- Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells (Q35093618) (← links)
- Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (Q35218943) (← links)
- Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. (Q35567765) (← links)
- Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia (Q35591409) (← links)
- NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT (Q35692428) (← links)
- IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity (Q35733767) (← links)
- The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide (Q35755295) (← links)
- Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. (Q35894369) (← links)
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells (Q36057599) (← links)
- Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells (Q36106330) (← links)
- Cytokine-induced killer (CIK) cells: from basic research to clinical translation (Q36121153) (← links)
- Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model (Q36137504) (← links)
- Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion (Q36351988) (← links)
- Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects (Q36380188) (← links)
- Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection. (Q36566943) (← links)
- Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma (Q36571270) (← links)
- Cytokine-induced killer cell therapy for the treatment of primary hepatocellular carcinoma subsequent to liver transplantation: A case report (Q36640769) (← links)
- Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer (Q36962962) (← links)
- Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation (Q37026059) (← links)
- IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy (Q37041732) (← links)
- Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells. (Q37084335) (← links)
- NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells (Q37406855) (← links)
- Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. (Q37492611) (← links)
- Early efficacy of stereotactic body radiation therapy combined with adoptive immunotherapy for advanced malignancies (Q37560863) (← links)
- Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform (Q37588329) (← links)
- In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells (Q37620831) (← links)
- New perspectives on the biology of acute GVHD. (Q37641063) (← links)
- Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells (Q37711663) (← links)
- Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation (Q37717313) (← links)
- Immunoregulation of GVHD by triggering the innate immune system with CpG (Q37810081) (← links)
- Mouse models of graft-versus-host disease: advances and limitations (Q37874011) (← links)
- Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors (Q37895924) (← links)
- LAK cell therapy of AML: Not to be lost in translation (Q37922827) (← links)
- New adoptive immunotherapy strategies for solid tumours with CIK cells (Q37996561) (← links)
- Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. (Q38002494) (← links)
- Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives (Q38574526) (← links)
- Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells (Q38740111) (← links)
- Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. (Q38787535) (← links)
- Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l (Q38827600) (← links)
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. (Q39026376) (← links)
- Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia (Q39049730) (← links)